Live Breaking News & Updates on Zachary Tramonti|Page 3

Stay updated with breaking news from Zachary tramonti. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ziopharm Comments on Delay of WaterMill's Stated Consent Deadline


Ziopharm Comments on Delay of WaterMill’s Stated Consent Deadline
Ziopharm Recommends Shareholders Return the
GREEN
Consent Revocation Card
BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, “WaterMill”) following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to deliver written consents in support of the Consent Solicitation. Ziopharm continues to strongly recommend shareholders sign and return the Company’s
GREEN Consent Revocation Card. ....

United States , Chris Kittredge , Zachary Tramonti , Andrew Cole , Robertw Postma , Michael Verrechia , Ziopharm Oncology Inc , National Cancer Institute , University Of Texas Md Anderson Cancer Center , Watermill Asset Management Corp , Exchange Commission , Corporate Communications , Sard Verbinnen Co , Ziopharm Recommends Shareholders Return , Ziopharm Oncology , Consent Solicitation , Sleeping Beauty , Sleeping Beauty Enabled , Cancer Center , Private Securities Litigation Reform Act , Quarterly Report , Additional Information , Consent Revocation Statement , Relations Contacts , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் ,

Egan-Jones Recommends Against Electing Dissident's Full Slate of Nominees to Ziopharm Board Nasdaq:ZIOP


s
Independent financial analysts widely recognize this progress:
“ZIOP continues to make progress with respect to the company-sponsored TCR-T program, the Controlled IL-12 program, and the Sleeping Beauty CAR-T program.”
2
“By unlocking the potential of its Sleeping Beauty technology, the Company is poised to deliver a leap forward in the personalization of cancer therapy.”
3
“We think that the company continues to make forward progress across its various platforms (TCR-T, CAR-T, and controlled IL-12).ZIOP has executed well over 2020 in curating immune receptors from its own libraries and it is moving forward its wholly owned program.”
4
The Company continues to urge shareholders to support Ziopharm’s continued progress and protect the value of their investment by signing and returning the ....

United States , Chris Kittredge , Raymond James , Zachary Tramonti , Andrew Cole , Michael Verrechia , Holger Weis , J Kevin Buchi , Jaime Vieser , Robertw Postma , Robert Postma , Services Egan Jones , Ziopharm Oncology Inc , National Cancer Institute , University Of Texas Md Anderson Cancer Center , Watermill Asset Management Corp , Exchange Commission , Cantor Fitzgerald , Oncology Inc , Corporate Communications , Institutional Shareholder Services , Sard Verbinnen Co , Shareholders Support Company Strong Progress , Shareholders Support Company , Strong Progress , Egan Jones Proxy Services ,